<DOC>
	<DOCNO>NCT01721096</DOCNO>
	<brief_summary>The objective PMS observe frequency , type , degree device deficiency assure safety new medical device ( XIENCE PRIME ) well collect information evaluation efficacy safety reevaluation .</brief_summary>
	<brief_title>XIENCE PRIME Japan Post-Marketing Surveillance ( PMS )</brief_title>
	<detailed_description>The primary objective PMS observe frequency , type , degree device deficiency assure safety new medical device ( XIENCE PRIME ) well collect information evaluation efficacy safety reevaluation Pharmaceuticals Medical Devices Agency ( PMDA ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<criteria>Patients ischemic heart disease eligible treatment XIENCE PRIME Everolimus Eluting Stent Patient provide Informed Consent Form If know time index procedure patient able return 8month followup visit angiogram 1year clinical followup , patient register PMS .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Real world</keyword>
</DOC>